Indaptus Therapeutics

Company snapshot

Indaptus Therapeutics is a pharma organization headquartered in NEW YORK, NY, USA. It trades on NYSE under ticker INDP. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 1 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• 1 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Indaptus Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Indaptus Therapeutics.

1. Aug 12, 2025 Patent grant

   Methods of treatment of infections using bacteria

View all clinical trial activity →

• What is Indaptus Therapeutics?

  Indaptus Therapeutics is a pharma organization headquartered in NEW YORK, NY, USA. It trades on NYSE under ticker INDP. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 1 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources

• Is Indaptus Therapeutics publicly traded?

  Yes. Indaptus Therapeutics is listed with ticker INDP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Indaptus Therapeutics develop or market?

  No drug profiles are currently linked to Indaptus Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for Indaptus Therapeutics?

  In the last 12 months our linked public records show 0 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Indaptus Therapeutics focus on?

  No specific therapeutic focus areas are currently identified for Indaptus Therapeutics in our database.